EPZM News and Press, Epizyme Inc. From 11/17/19

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 131 weeks of public selections as part of this ongoing live forward-testing. In...

NEW YORK , Nov. 5, 2019 /PRNewswire/ -- Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of tazemetostat, Epizyme Inc.'s (Nasdaq: EPZM) lead investigational agent, outside of Japan , and made an equi...

Epizyme ( EPZM +6.3% ) is up on below-average volume in reaction to its agreements with Royalty Pharma and its affiliate Pharmakon Advisors that, it says, could raise up to $270M in new capital, extending its cash runway into at least 2022. More news on: Epizyme, Inc., Eisai Co., Ltd.,...

$100 Million Upfront Investment by Royalty Pharma with Up to $100 Million in Future Equity Existing Royalty Obligation on Future Tazemetostat Sales Reduced with Royalty Pharma $70 Million Expandable Loan Facility with Pharmakon Advisors to Fund Anticipated Regulatory Milestone P...

Epizyme (NASDAQ: EPZM ): Q3 GAAP EPS of -$0.40 beats by $0.15 . More news on: Epizyme, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Pre-NDA Meeting Supports Registration Strategy for Tazemetostat for Follicular Lymphoma Patients with and without EZH2 Activating Mutations and Planned NDA Submission in December 2019 Updated Phase 2 Follicular Lymphoma Data Selected for Oral Presentation at ASH Finalized U.S. Lau...

Although shares of Epizyme (NASDAQ: EPZM) are trading at a fraction of the all-time high achieved shortly after the initial public offering in 2013, the company's current market valuation of $1.2 billion is close to a high-water mark. Investors can thank a surge in stock dilution (which keep...

Epizyme, Inc . (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointments of experienced commercial executive, Grant Bogle, and research and development executive, Victoria Richon, Ph.D., to the company’s board of dir...

Epizyme, Inc . (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in the following September investor conferences: Citi 14 th Annual Biotech Confere...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 117 weeks of public selections as part of this ongoing live forward-testing. ...